Huons Signs Co-Marketing Agreement for Rheumatoid Arthritis Drug 'Lipotoson'

KIMS Pharmaceutical's rheumatoid arthritis treatment 'Lipotasone Injection (active ingredient Dexamethasone Palmitate)'
[Photo by Huons]

Huons recently announced on the 30th that it has signed a co-promotion agreement with KIMS Pharmaceutical for the rheumatoid arthritis treatment ‘Lipothason Injection (Lipothason, active ingredient dexamethasone palmitate)’.

Lipothason Injection is an anti-inflammatory treatment developed by the Japanese pharmaceutical company Mitsubishi Tanabe Pharma. It is the only liposome nanoparticle (LNPS) steroid injection in Korea, with 83?95 nm nanoparticle Lipothason selectively exerting its effects on targeted lesion sites, minimizing drug efficacy loss and demonstrating strong effects at the target area. It reduces the side effects of conventional steroid injections, allowing administration via intravenous injection (IV), epidural, and intrathecal routes.

Huons expects Lipothason Injection to establish itself as a new option in pain treatment by enhancing safety and therapeutic effects. They also anticipate synergy with Huons’ existing pain treatment products.

Yoon Sang-bae, CEO of Huons, stated, “Through this partnership, we can provide a rheumatoid arthritis treatment with confirmed strong therapeutic effects and safety,” adding, “We will strive to establish Lipothason Injection as a new treatment option in the field of pain management.”

This content was produced with the assistance of AI translation services.